Form 4: Theriva Biologics Director, Jeffrey J. Kraws, Reports Stock Option Grant

Director Jeffrey J. Kraws reports acquisition of stock options in Theriva Biologics, Inc.

Summary

• Jeffrey J. Kraws, a director of Theriva Biologics, Inc., filed a Form 4 with the SEC.
• The report details the grant of stock options to Kraws on April 29, 2025.
• Kraws acquired options to purchase 25,000 shares of common stock at an exercise price of $1.4144.
• The options vest monthly over 12 months, beginning May 1, 2025, and expire on April 29, 2032.
• Following the transaction, Kraws directly owns 25,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant could incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, stock options, Theriva Biologics, TOVX, director, Jeffrey J. Kraws, beneficial ownership, SEC